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Abstract
Background: Previous data suggest that mitral valve leaflets are elongated in hypertrophic cardiomyopathy (HCM),
and mitral valve leaflet elongation may constitute a primary phenotypic expression of HCM. Our objective was to
measure the length of mitral valve leaflets by cardiovascular magnetic resonance (CMR) in subjects with HCM
caused by a Finnish founder mutation in the myosin-binding protein C gene (MYBPC3-Q1061X), carriers of the
same mutation without left ventricular hypertrophy, as well as in unselected consecutive patients with HCM, and
respective controls.
Methods: Anterior mitral valve leaflet (AML) and posterior mitral valve leaflet (PML) lengths were measured by CMR
in 47 subjects with the Q1061X mutation in the gene encoding MYBPC3 and in 20 healthy relatives without the
mutation. In addition, mitral valve leaflet lengths were measured by CMR in 80 consecutive non-genotyped patients
with HCM in CMR and 71 age- and gender-matched healthy subjects.
Results: Of the subjects with the MYBPC-Q1016X mutation, 32 had left ventricular hypertrophy (LVH, LV maximal
wall thickness ≥ 13 mm in CMR) and 15 had no hypertrophy. PML was longer in patients with the MYBPC3-Q1061X
mutation and LVH than in controls of the MYBPC group (12.8 ± 2.8 vs 10.6 ± 1.9 mm, P = 0.013), but the difference
between the groups was not statistically significant when PML was indexed for BSA (P = 0.066), or when PML
length was adjusted for BSA, age, gender, LV mass and ejection fraction (P = 0.195). There was no significant
difference in the PML length in mutation carriers without LVH and controls (11.1 ± 3.4 vs 10.6 ± 1.9, P = 0.52). We
found no difference in AML lengths between the MYBPC mutation carriers with or without hypertrophy and
controls. In 80 consecutive non-genotyped patients with HCM, there was no difference either in AML or PML
lengths in subjects with HCM compared to respective control subjects.
Conclusions: In subjects with HCM caused by the Q1061X mutation in the MYBPC3 gene, the posterior mitral valve
leaflets may be elongated, but mitral valve elongation does not constitute primary phenotypic expression of the
disease. Instead, elongated mitral valve leaflets seem to be associated with body size and left ventricular remodeling.
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Background
Hypertrophic cardiomyopathy (HCM) is the most com-
mon genetic cardiomyopathy with an estimated prevalence
of 1:500 in the general population [1]. It is also the most
common cause of sudden cardiac death among young
people and athletes [2]. HCM is inherited as an autosomal
dominant trait and at the moment over 1400 mutations in
at least 13 different HCM-causing genes encoding mainly
cardiac sarcomeric proteins have been identified [2]. The
penetrance of mutations is highly variable and incomplete
[3]. Left ventricular hypertrophy (LVH) in HCM usually
develops during adolescence, but particularly myosin
binding protein C (MYBPC3) mutations are slower to
manifest and mutation carriers often demonstrate onset of
hypertrophy later in life [4].
Mutations in the cardiac myosin-binding protein C
(MYBPC3) gene are a common cause of HCM. It is
estimated that 42 % of the mutations causing HCM are
found in the MYBPC3 gene [5]. The most common
single mutation responsible for HCM in Finland is the
founder mutation Q1061X in the MYBPC3 gene
(MYBPC3-Q1061X). It accounts for approximately 11 %
[6] of the Finnish HCM cases [6, 7]. This mutation is
characterized by a relatively low penetrance, and it is
rare outside Finland. In patients with MYBPC3-Q1061X,
marked hypertrophy and significant arrhythmias may
occur, but in most cases the phenotype is mild [6, 8].
Several traditional echocardiographic studies have
reported that mitral valve is elongated in HCM, particu-
larly in the obstructive form of the disease [9–12].
Quantitative characterization of mitral valve length by
echocardiography is, however, inaccurate. Cardiovascular
magnetic resonance (CMR) may provide a more accurate
method to characterize mitral valve, but so far, there are
no generally accepted normal values for mitral valve
leaflet lengths measured by CMR. In the study by Maron
et al., patients with HCM had significantly longer anter-
ior and posterior mitral valve leaflets (AML and PMLs,
respectively) compared to controls. Moreover, elongated
anterior mitral valve leaflets seemed to represent a
primary phenotypic expression of HCM, as subjects with
HCM-causing sarcomeric mutations but no LVH had
elongated AMLs [13]. Recently, also Captur et al.
reported two CMR studies suggesting that elongated
AML is a feature of sarcomeric mutation induced
subclinical HCM [14, 15], and Reant et al. found longer
AMLs in G+/LVH- subjects compared to controls in
their study [16].
Therefore, as the knowledge of mitral valve length in
clinical and subclinical HCM is quite limited, the aim of
the present study was to investigate mitral valve leaflet
length in carriers of the single MYBPC3-Q1016X
mutation, with and without LVH and mutation negative
relatives without hypertrophy by CMR. In addition, we
measured mitral valve leaflets in CMR images of 80
consecutive non-genotyped patients with HCM criteria
in CMR, and matched controls with normal CMR.
Methods
Study population and echocardiography
In the MYBPC study, we screened 74 adult individuals
from 25 families carrying the Finnish founder mutation
MYBPC3-Q1061X for inclusion at the University
Hospitals of Helsinki and Kuopio. We prospectively
invited all available subjects with MYBPC3-Q1061X mu-
tation (G+) and their healthy relatives without mutation
(G-) from Kuopio and Helsinki University Hospital
areas, and included all who were willing to participate in
the study. The genetic diagnosis was performed at the
Genome Center of the University of Eastern Finland as
previously described [6]. Seven screened individuals were
excluded from the study due to having a pacemaker or
implantable cardioverter defibrillator (ICD). The final
study population included 47 subjects with the
MYBPC3-Q1061X mutation, and 20 healthy relatives
without the MYBPC3-Q1061X mutation from the same
families. Echocardiographic studies were performed by
experienced cardiologists with Vivid 7 (GE Vingmed,
Norway) ultrasound equipment and analyzed with
Echopac software (GE Vingmed, version 10.0.1, Norway).
Mitral regurgitation was determined and graded by color
Doppler. Left ventricular outflow tract (LVOT) maximal
flow velocity was measured by continuous wave Doppler
(gradient > 30 mmHg on echocardiography considered
significant).
The G+/LVH+ group of the MYBPC study consisted
of 32 patients with MYBPC-Q1061X mutation and
significant hypertrophy consistent with HCM pheno-
type (LV maximal wall thickness ≥ 13 mm in CMR).
The G+/LVH- group consisted of 15 subjects with
MYBPC3-Q1061X mutation and no HCM phenotype
(LV maximal wall thickness < 13 mm in CMR). The
control population consisted of 20 healthy relatives
without the MYBPC3-Q1061X mutation. The local
ethics committees of the University Hospitals of
Helsinki and Kuopio approved the study protocol and
all subjects gave prior written consent.
In the Archive study, of all 80 consecutive unselected
individuals with HCM criteria (LV maximal wall
thickness ≥ 13 mm, in the absence of other causes for
LVH, such as aortic stenosis or hypertensive heart
disease) in CMR diagnosed by referred radiologist at the
Kuopio University Hospital from April 2005 to June
2012, were included in the Archive HCM group. In
addition, 71 individuals with normal CMR findings, who
were matched with patients with HCM in the Archive
substudy with respect to age and sex in unpaired fash-
ion, were obtained from the Kuopio University Hospital
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picture archiving and communication system (PACS) to
be included in the Archive control group. In Archive-
HCM patients, genetic cause of the disease was not
systematically defined, although some of the patients
may have been detected to have one of the three Finnish
founder mutations causing HCM [6–8]. In archive pa-
tients, CMR was performed as a part of clinical patient
care and consequently, no consent was obtained. The
ethics committee of the Kuopio University Hospital
accepted the use of CMR data of archive patients as a
part of the present study (17/4/2012).
CMR
In the MYBPC study, CMR was performed prospectively
according to the same study protocol in two participat-
ing university hospitals (Kuopio University Hospital and
Helsinki University Hospital). Imaging was performed by
using a 1.5 T scanner (Magnetom Avanto; Siemens
Medical Solutions, Erlangen, Germany) and a body-array
coil in both participating hospitals. After scout images
were obtained, 8-mm sections with retrospectively ECG-
gated steady-state, free precession breath-hold cine
images in 3 standard long-axis planes (4-, 3- and 2-
chamber views) and sequential 8-mm short axis slices
from atrium to apex with an intersection gap of 20 %
were acquired. The typical parameters used to perform
cine CMR were as follows: 48/1.1 (repetition time msec/
echo time msec), a 65° flip angle, a 192 × 256 matrix, and
a 280–360-mm field of view.
In the Archive group, all consecutive unselected
subjects were imaged as part of the clinical work with
the same scanner and with the same imaging protocol,
planes and sequences as in the MYBPC study.
Image analyses
Image analysis was performed by using Sectra IDS7/dx
workstation. The radiologists analyzing CMR images
were blinded to genetic and clinical findings of the study
subjects. The lengths of anterior mitral leaflet (AML)
and posterior mitral leaflet (PML) were measured in the
cine 3-chamber view image, from the most distal part of
the leaflet to its insertion in mid- or end-diastole, using
the last diastolic image where the MV was clearly visible
(Fig. 1) [13, 17, 18]. One radiologist (M.T., with 5 year
experience in CMR) performed all mitral valve length
measurements on MR images. LVMWT was measured
at end-diastole in the short-axis orientation in all 67
subjects of the MYBPC study by one radiologist (K.L.)
with over 20 year experience in CMR, and by clinical
radiologists in the Archive study. To evaluate left
ventricular ejection fraction (LVEF), left ventricular end-
diastolic volume (LVEDV), left ventricular mass (LVM)
and left ventricular end-systolic volume (LVESV), the
endocardium and the epicardium were manually traced,
with the papillary muscles and trabeculations excluded.
LVESV was analyzed from the cine images with smallest
LV cavity. The other measurements were performed of
the first image after R-wave. LV analyses were performed
with dedicated software (Argus, Siemens, Erlangen,
Germany) [19] by a single radiologist (M.T.) in the
MYBPC study, and by clinical radiologists in the Archive
study. Body surface area (BSA) was calculated by using
Du Bois method.
To evaluate mitral valve leaflet length measurement
repeatability, mitral valve leaflets were re-measured in 20
randomly selected subjects with the MYBPC3-Q1061X
mutation. To study intraobserver variability, one radiolo-
gist (M.T.) measured mitral valve leaflet lengths twice,
with at least 3 months between the measurements. To test
interobserver variability, second observer (K.H.) repeated
the same measurements in the same set of 20 subjects.
Statistical analyses
Baseline continuous data are expressed as mean ± SD.
As many of the variables studied were not normally
distributed, they were compared with Kruskal-Wallis
one-way analysis of variance (the MYBPC-group) and
independent samples Mann-Whitney U test (the
Archive-group), when appropriate. Adjustments were
done by using general linear model. Spearman correl-
ation coefficients were used to study the association of
AML and PML lengths with clinical, echocardiographic
and CMR findings. Paired samples T-test was used for
comparing age and sex matched G+/LVH- and controls
and also in repeatability testing. Intraclass correlation
coefficients (ICC) were determined. SPSS 19.0 (SPSS
Inc, Chicago, IL, USA) was used for statistical analyses.
A P value less than 0.05 was considered significant.
Fig. 1 Measurement of mitral valve leaflets in 3-chamber diastolic
image. Anterior mitral leaflet (AML) is indicated in thin arrows and
posterior mitral leaflet (PML) in thick arrows. RV = right ventricle,
LV = left ventricle, AO = aorta, LA = left atrium
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Results
Clinical, echocardiographic and CMR characteristics
Clinical, echocardiographic and CMR findings of the
study subjects are presented in Table 1. In the MYBPC
group, G+/LVH- subjects were younger than G+/LVH+
subjects and controls, as expected and had also lower
BSA. There were more male subjects in the G+/LVH+
group than in the G+/LVH- and control groups. Body
surface area (BSA) was lower in the G+/LVH- group
compared to other groups.
None of the study subjects of the MYBPC study had a
history of surgical septal myectomy or alcohol septal
ablation, or mitral valve prolapse or significant mitral
regurgitation on echocardiography. Altogether, 18 study
subjects had insignificant grade 1/4 mitral regurgitation.
There was one patient with significant left ventricular
outflow tract obstruction (gradient > 30 mmHg on echo-
cardiography) in the MYBPC G+/LVH+ group, but there
were no significant difference in the mean LVOT gradi-
ents between the three MYBPC study groups. In CMR,
there were expected differences between the MYBPC
subgroups in LVMWT and in left ventricular mass index
(LVMI), but no significant differences in ventricular vol-
ume indices (LVEDVI and LVESVI) or in LVEF between
the three MYBPC study groups. In CMR, LVH in the G
+/LVH+ patients was mostly quite moderate, with asym-
metric distribution in the anteroseptal wall. Of G+/LVH
+ patients, 72 % had septal and 25 % anterior wall hyper-
trophy. None of the subjects had true apical hypertrophy
limited to apex.
In the Archive group, there was no significant differ-
ence in age, gender distribution or BSA between patients
with HCM and controls. There was expected difference
in LVMWT between the patients with HCM and
controls. In addition, LVESVI was smaller and LVEF
higher in the HCM group compared to the respective
control group.
Mitral valve leaflet lengths
Table 1 and Figs. 2 and 3 show the lengths of AML and
PML in the study groups. In the MYBPC study, views
were suitable for mitral valve leaflet measurements in
95 % of the study subjects for AML and 91 % for PML.
There was no difference in AML lengths between the
MYBPC study subgroups, irrespective of indexing for
BSA (Figs. 2 and 4). The indexed AML was even shorter
in the MYBPC G+/LVH+ group than in other two
groups. We also indexed AML for LVEDV and the
Table 1 Clinical, echocardiographic and cardiac MRI (CMR) findings in the MYBPC group and in the Archive group
MYBPC control MYBPC G+/LVH- MYBPC G+/LVH+ P Archive control Archive HCM P
Patients, n 20 15 32 71 80
Age, y 46 ± 17 33 ± 16 50 ± 11 .007* 53 ± 14 55 ± 16 .42
Men, n 5 (25 %) 3 (20 %) 20 (63 %) <.001* 44 (62 %) 51 (64 %) .82
BSA, m2 1.87 ± 0.28 1.75 ± 0.18 1.94 ± 0.20 .004* 1.88 ± 0.22 1.90 ± 0.21 .44
Height, cm 169 ± 10 167 ± 6 174 ± 9 .040* 171 ± 10 170 ± 8 .718
Weight, kg 76 ± 24 68 ± 13 81 ± 14 .005* 77 ± 16 80 ± 16 .248
BMI 27 ± 8 24 ± 4 27 ± 4 .129 26 ± 4 28 ± 5 .141
NYHA, n
I 20 (100 %) 15 (100 %) 28 (88 %) N.A. N.A.
II - - 4 (13 %) N.A. N.A.
LVOT gradient, mmHg 7.1 ± 2.9 5.7 ± 1.8 8.5 ± 11.4 .42 N.A. N.A.
LVMWT, mm 10.2 ± 2.8 9.5 ± 1.6 22.1 ± 5.7 <.001* 10.5 ± 2.5 19.2 ± 4.5 <.001*
LVMI, g/m2 45 ± 9 49 ± 13 68 ± 21 <.001* N.A. N.A.
LVEDVI, ml/m2 78 ± 13 78 ± 15 74 ± 14 .55 75 ± 17 74 ± 22 .49
LVESVI, ml/m2 32 ± 10 30 ± 7 28 ± 10 .13 33 ± 9 31 ± 15 .019*
LVEF, % 60 ± 8 62 ± 5 63 ± 9 .12 55 ± 7 59 ± 10 .007*
AML, mm (range) 25.0 ± 2.9 (20–30) 24.7 ± 3.8 (19–33) 24.8 ± 4.1 (19–42) .81 25.1 ± 3.7 (16–36) 25.3 ± 3.9 (17–41) .66
PML, mm (range) 10.6 ± 1.9 (8–15) 11.1 ± 3.4 (6–16) 12.7 ± 2.8 (9–22) .056 14.4 ± 3.6 (7–24) 14.2 ± 3.5 (8–25) .55
AML index, mm/m2 13.7 ± 2.2 14.2 ± 2.2 12.9 ± 2.5 .034* 13.5 ± 2.4 13.8 ± 2.5 .68
PML index, mm/m2 5.8 ± 1.2 6.2 ± 1.5 6.6 ± 1.5 .214 7.8 ± 2.2 7.6 ± 1.9 .90
MYBPC-control healthy controls without MYBPC mutation, MYBPC G+/LVH- MYBPC mutation carriers without LVH, MYBPC G+/LVH+ MYBPC mutation carriers with LVH,
Archive control control subjects with normal CMR findings, Archive HCM subjects with HCM in CMR, BSA body surface area, BMI body mass index, NYHA New York Heart
Association functional class, LVOT gradient left ventricular outflow tract gradient, LVMWT left ventricular maximal wall thickness, LVMI left ventricular mass index, LVEDVI
left ventricular end-diastolic volume index, LVESVI left ventricular end-systolic volume index, LVEF left ventricular ejection fraction, AML anterior mitral leaflet length, PML
posterior mitral leaflet length, AML index AML indexed for BSA, PML index PML indexed for BSA, N.A. not available. * Significance P < 0.05
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difference between the MYBPC groups was insignificant
(P = 0.460). There was one subject in both G+ subgroups
in whom the length of AML exceeded + 2SD of the
mean length of AML of the control group (Fig. 2).
In contrast, there was a difference of borderline statis-
tical significance in the length of PML between the
MYBPC subgroups (Table 1, Fig. 3). PML was found to
be significantly longer in the MYBPC G+/LVH+ group
compared to the control group (12.8 ± 2.8 vs 10.6 ±
1.9 mm, P = 0.013) [Table 1]. When indexed for BSA,
however, there was no significant difference in the PML
length between the MYBPC G+/LVH+ group and the
control group (6.6 ± 1.5 vs 5.8 ± 1.2 mm/m2, P = 0.066)
(Table 1, Fig. 5). When PML was adjusted for age, gender
and BSA, there was significant difference (P = 0.045)
between the two groups. However, when further adjusted
Fig. 2 Anterior mitral valve leaflet (AML) lengths in study groups. The lower edge of the box presents 25th percentile and the upper edge 75th
percentile. A line across the box is the median. The small circles present outliers and asterisk extreme value. There is no significant difference
between the three and two groups, respectively
Fig. 3 Posterior mitral valve leaflet (PML) lengths in study groups. The lower edge of the box presents 25th percentile and the upper edge 75th
percentile. A line across the box is the median. The small circles present outliers. There is a significant difference between MYBPC genotype-positive/
phenotype-positive (G+/LVH+) subjects and MYBPC-controls (P = 0.013)
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for LVM and LVEF, the difference in PML length was no
longer significant between the MYBPC G+/LVH+ group
and the control group (P = 0.195). We also indexed PML
for LVEDV and the difference was insignificant between
the MYBPC groups (P = 0.142).
There was no significant difference between the
MYBPC G+/LVH- group and control group (11.1 ± 3.4
vs 10.6 ± 1.9 mm, P = 0.598) in PML lengths or BSA
indexed PML lengths. As there was a difference in age
and sex distribution between these two groups, we also
selected age (±3 years) and sex matched control to each
G+/LVH- subject and compared them pairwise. There
was not any difference in mitral valve leaflet lengths, or
in indexed leaflet lengths, in phenotype negative
MYBPC3-Q1061X mutation carriers and controls (25.4
vs 26.0 mm, P = 0.726 for AML and 11.2 vs 10.6 mm, P =
Fig. 4 AML lengths indexed for body surface area (BSA) in study groups. The lower edge of the box presents 25th percentile and the upper edge
75th percentile. A line across the box is the median. The small circles present outliers and asterisk extreme value. There is a significant difference
between MYBPC genotype-positive/phenotype-positive (G+/LVH+) subjects and MYBPC-controls (P = 0.037)
Fig. 5 PML lengths indexed for body surface area (BSA) in study groups. The lower edge of the box presents 25th percentile and the upper edge
75th percentile. A line across the box is the median. The small circles present outliers and asterisk extreme value. There is no significant difference
between the three and two groups, respectively
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0.680 for PML, and 14.3 vs 14.5 mm, P = 0.881 for
BSA-indexed AML and 6.1 vs 5.9 mm, P = 0.729 for
BSA-indexed PML, respectively) in matched pairwise
comparison.
We found six subjects (19 %) in the MYBPC G+/LVH+
group and three subjects (20 %) in the MYBPC G+/LVH-
group in whom the length of PML exceeded + 2SD of the
mean length of PML of the control group.
In the Archive-group, AML could be measured in
95 % and PML in 88 % of the subjects. There was no
difference in either AML lengths or PML lengths, or
BSA indexed mitral valve leaflet lengths, between
Archive-HCM patients and their matched control sub-
jects (Table 1, Figs. 2 and 3). We tested AML and PML
lengths after indexing for LVEDV and no significant
difference between the Archive study groups was found
(P = 0.328 for AML and P = 0.556 for PML). We also
studied the mitral valve leaflet lengths including only the
Archive-HCM patients with LVMWT 15 mm or more
(instead of 13 mm or more) in the analysis, and there
were no significant difference in mitral valve leaflet
lengths compared to the controls (AML 25.8 ± 3.8 vs
25.1 ± 3.7 mm, P = 0.480, and PML 14.2 ± 3.4 vs 14.4 ±
3.6 mm, P = 0.585). There were 2 subjects in the
Archive-HCM group in whom the length of AML
exceeded + 2SD of the mean length of AML of the
Archive-control group, and 3 subjects in whom the
length of PML exceeded + 2SD of the mean length of
PML of the Archive-control group.
Relation of mitral valve length to left ventricular and
clinical parameters
Table 2 shows associations between mitral valve leaflet
lengths and clinical, echocardiographic and CMR findings
in patients with MYBPC-Q1061X mutation (G+/LVH+
and G+/LVH- groups combined). In patients with
MYBPC-Q1061X mutation (G+/LVH+ and G+/LVH-
groups combined), PML length correlated with BSA
(r = 0.405, P = 0.014), LVM (r = 0.379, P = 0.023), and
reduced LVEF (r = −0.407, P = 0.014). AML length was as-
sociated with increased LVM only (r = 0.314, P = 0.036).
There was no association between mitral valve leaflet
length and age, gender or LVOT gradient.
In the Archive-HCM group, AML length correlated
with left ventricular volumes (LVEDV and LVESV) and
negatively with LVEF. PML did not correlate with any
clinical, echocardiographic or CMR parameters in the
Archive-HCM group.
Reproducibility of mitral valve measurements
In intraobserver analysis measurements, no difference
between first and second measurements of the AML
(25.4 ± 2.4 vs 25.3 ± 2.8 mm, P = 0.586) and PML (13.0 ±
3.4 vs 13.1 ± 4.4 mm, P = 0.784) lengths was found. Also
the correlation between the measurements was al-
most perfect for AML (r = 0.949, P < 0.001) and for
PML (r = 0.928, P < 0.001). In interobserver measure-
ments, there were a systematic differences in AML
(25.5 ± 4.6 vs 27.3 ± 6.5, P = 0.08) and PML (12.7 ± 3.1
vs 13.9 ± 3.0, P = 0.03) lengths between observers. In
correlation analysis there were relatively good agreements
between the measurements by two observers (r = 0.741,
P < 0.001) for AML and (r = 0.657, P = 0.001) for PML.
Discussion
Principal findings
In the present study, patients with the MYBPC3-
Q1061X mutation and LVH had slightly elongated pos-
terior mitral valve leaflets (PMLs) compared to controls,
but there was no difference between the groups when
mitral valve leaflets were indexed for BSA, or adjusted
for BSA, age, gender, LV mass and ejection fraction. In
the MYBPC3 mutation carriers without LV hypertrophy,
there was no difference in PML length compared to the
MYBPC control group. In subjects with MYBPC-
Q1061X mutation, including subjects with and without
LVH, PML length correlated with BSA, LVM and
reduced LVEF. No difference in AML length between
the MYBPC3 mutation carriers, with or without hyper-
trophy and controls was found. In the non-genotyped
unselected consecutive subjects with HCM of the
Archive group, there was no difference in AML or PML
lengths compared to control subjects.
In the context of current literature
Recent studies indicate that CMR may be useful for
establishing mitral valve morphology and pathology [20].
Table 2 Spearman correlation coefficients between mitral leaflet
length and clinical, echocardiographic and CMR findings in
MYBPC G + and Archive-HCM groups
MYBPC G+ Archive-HCM
AML PML AML PML
age .015 −.035 .050 .051
sex .079 .309 −.079 .173
BSA .098 .405* −.035 .080
LVOT gradient .257 −.241 N.A. N.A.
LVMWT .161 .152 −.020 .026
LVM .314* .379* N.A. N.A.
LVEDV .196 .326 .301* .060
LVESV .215 .326 .348* .109
LVEF −.028 −.407* −.250* −.078
AML anterior mitral valve leaflet, PML posterior mitral valve leaflet, BSA body
surface area, LVOT gradient left ventricular outflow tract gradient, LVMWT left
ventricular maximal wall thickness, LVM left ventricular mass, LVEDV left
ventricular end-diastolic volume, LVESV left ventricular end-systolic volume,
LVEF left ventricular ejection fraction
*Significance P < 0.05
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At the moment, however, there are no reference values
for mitral valve leaflet lengths measured by CMR. So far,
there are only four published CMR studies on mitral
valve leaflet lengths in patients with HCM, or with
HCM-causing sarcomeric mutations but no LVH
[13–15]. These previous studies have shown elon-
gated anterior and posterior mitral valve leaflets in
172 patients with non-genotyped HCM compared to
control subjects [13], and elongated anterior mitral
valve leaflets in subjects with HCM-causing muta-
tions but no LVH [13–15]. In the study by Maron et
al., 15 G+/LVH- subjects with mutations in MYBPC3,
β myosin heavy chain and troponin T genes were
studied [13]. In the studies by Captur et al., there were 73
and 40 G+/LVH- subjects with mutations in MYBPC3,
MYH7, MYL2, MYL3, TNNT2, TNNI3, TPM1 and
ACTC1 genes, respectively [14, 15]. In the recent study by
Reant et al., 36 G+/LVH- subjects had mutations in the
same genes [16] as in the studies by Captur.
In the present MYBPC study, in which all G+ subjects
had a single MYBPC-Q1016X mutation, we found that
some HCM patients with hypertrophic phenotype have
elongated PML consistent with the concept that mitral
valve leaflets may be elongated in HCM. However, in 80
non-genotyped unselected consecutive subjects with
HCM of the Archive group, there was no difference in
AML or PML lengths compared to control subjects, sug-
gesting that mitral valve elongation is not a consistent
feature of HCM in all its subpopulations. Furthermore,
our study does not support the suggestion that mitral
valve lengthening represents a primary phenotypic
expression of the disease, as first, there was not any kind
of difference in AML or PML lengths between the
apparently healthy MYBPC3-Q1061X mutation carriers
and controls; and second, the difference in PML length
between the G+/LVH+ group and the control group was
not significant after indexing for BSA, or when adjusted
for BSA, age, gender, LV mass and ejection fraction.
Possible mechanisms of elongated mitral valve leaflets
We found a positive association between PML length
and BSA in MYBPC mutation carriers. Hence, mitral
valve length, as many other structures of the heart, may
be related to body size. However, PML length did not
correlate with BSA in the Archive-HCM group. Further-
more, AML length did not correlate with BSA in the
MYBPC G+ or Archive-HCM study groups. Conse-
quently, studies in larger normal and patient populations
are needed to confirm if mitral valve length is related to
body size, and to define normal values of CMR derived
mitral valve leaflet length.
In carriers of the MYBPC3-Q1061X mutation, PML
length correlated with reduced EF and LVM, and AML
length correlated with LVM. There was also a significant
correlation between increased AML length and LV
volume and reduced EF in subjects with HCM of the
Archive group. Our findings suggest that mitral valve
leaflet elongation may be related to LV remodeling in
HCM. Cardiac remodeling, characterized by increased
LVM, increased LV volumes and lower EF, may mechan-
ically stretch the valve apparatus, leading to elongated
mitral valve leaflets. In the Archive group of the present
study, subjects with HCM had comparatively mild
phenotype with moderate LVH and normal LV volumes,
which may explain that, in contrast to the previous study
[13], no significant elongation of mitral valve leaflets in
these patients was observed.
LVOT obstruction is often associated with elongated
mitral valve leaflets [12]. In the present study, significant
LVOT obstruction was found only in one patient of
MYBPC study, and consequently, the present study is
not suitable for investigating the impact of LVOT obstruc-
tion on CMR derived mitral valve leaflet lengths. Respect-
ively, low prevalence of LVOT obstruction (a history of
myectomy in 2 % and LVOT flow velocity >2.75 m/s in
7.5 % of subjects) was found in our previous study on 306
Finnish patients with HCM, of which 35 had MYBPC3-
Q1061X mutation [6].
It has been suggested that mitral valve abnormal-
ities might be a primary phenotypic expression of
HCM [13–15]. Sarcomeric mutations account for
about 60 % of HCM cases, and variable sarcomeric
genes, including troponin T, I and C, beta-and alpha
myosin heavy chain, and myosin light-chain 2 genes,
are expressed in interstitial cells of human heart
valves [21]. According to current knowledge, however,
MYBPC3 gene is expressed exclusively in cardiac
muscle, and we have not found evidence that it is
expressed in heart valves [22]. Consequently, primary mi-
tral valve elongation might be evident only in HCM caused
by mutations in genes that are expressed in heart valves.
Furthermore, HCM-causing mutations in genes encoding
sarcomere proteins induce LVH by at least two different
mechanisms, incorporation of the mutant protein in the
sarcomere, or haploinsufficiency due to absence of the mu-
tant protein in the sarcomere [2, 23], respectively. Conse-
quently, it is possible that not only the HCM-causing gene
but also the mutation type may influence the disease ex-
pression in mitral valve. This highlights the importance to
study mitral valve leaflet lengths in a sufficient number of
subjects with identical HCM-causing mutations. Further
larger studies are needed to clarify if mitral valve leaflets
are elongated in subjects with mutations in variable HCM-
associated genes and different type of gene variants.
Study limitations and strengths
Although our MYBPC3-Q1016X genotype-positive study
population is relatively small, it includes a moderate
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number of subjects with a single HCM-causing mutation.
Thus, the confounding effect of variable disease-causing
mutations on the valve length is avoided. MYBPC muta-
tions are the most common cause of HCM, and represent
42 % percent of all HCM cases globally [5]. The Finnish
founder mutation MYBPC-Q1016X, which is the most
common genetic cause for HCM in Finland, is rare
outside Finland. It might, however, be regarded to be
representative of most MYBPC mutations, as like two
thirds of all MYBPC3 mutations and consequently, about
a third of all HCM-causing mutations globally, it leads to
the production of a truncated protein and, consequently,
to haploinsufficiency, characterized by absence of mutant
protein in myocytes [22–24].
The number of mutation carriers without LVH was
small in the present study, and they were younger and
had a smaller BSA than the control subjects. However,
not only the non-indexed but also the BSA-indexed
mitral valve leaflet lengths in mutation carriers without
LVH were similar to those of the control group, without
even a trend for elongated leaflets in mutation carriers.
Furthermore, when compared pairwise with age and sex
matched controls, there was not any difference in mitral
valve leaflet lengths in phenotype negative MYBPC3-
Q1061X mutation carriers. On the basis of the present
study, CMR-derived mitral valve length is not useful in
identifying subjects with HCM-causing gene mutations
but without LVH.
The number of consecutive unselected Archive HCM
subgroup subjects of the present study was large and
representative of all patients with HCM in the Kuopio
University Hospital area. The subjects were well-matched
with control subjects for age and gender, and in contrast
to previous studies, mitral valve length was indexed for
BSA, making it unlikely that the results of the Archive
study are biased.
Finally, the reproducibility of mitral valve measure-
ments was very high, with excellent intraobserver and
acceptable interobserver variability, supporting the validity
of the findings of the present study.
Conclusions
In subjects with HCM caused by the Q1061X mutation
in the MYBPC3 gene, posterior mitral valve leaflets may
be elongated, but mitral valve elongation does not
constitute primary phenotypic expression of the disease.
Instead, elongation of mitral valve leaflets in HCM
seems to be associated with body size and left ventricu-
lar remodeling.
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